Patient profile
Adult patient. Resident of a Gulf metropolitan area. Diagnosis category: solid-tumor oncology, second-line therapy indicated after first-line failure at a regional tertiary oncology center.
Patient
Adult, Gulf metropolitan area
Diagnosis category
Solid-tumor oncology
Line of therapy
Second-line, post first-line failure
Care setting
Regional tertiary oncology center
The access wall
The treating oncologist had identified the appropriate next-line therapy. The therapy is approved and stocked routinely in the United States. Local registration in the patient's country of residence had not yet completed, and the specialty-distributor channel did not list the product.
The family could pay cash. The clinical decision was made. The channel between the prescription and the dose was the only variable.
The Reserve Meds path
-
Day 0. Intake.
Treating physician contacted Reserve Meds directly. Single Concierge Patient Coordinator assigned to the case for full continuity.
-
Day 1 to Day 3. Documentation.
Prescription on physician letterhead, treatment summary, and patient identity documents collected on patient consent. KYC, AML, and OFAC screens cleared. HIPAA authorization and country-specific data consent recorded.
-
Day 3. Indicative quote.
Range disclosed pre-document review based on therapy class and destination geography.
-
Day 4 to Day 7. Source confirmation and firm quote.
Manufacturer or authorized US distributor source confirmed. DSCSA chain-of-custody documentation generated to export point. Firm quote issued post-document review. Contract executed. Payment received into segregated escrow.
-
Day 8 to Day 12. Ship and deliver.
Cold-chain shipment dispatched on a named carrier with temperature telemetry. Importer-of-Record cleared customs in destination country. Delivery confirmed at the treating clinic on Day 12. First dose administered by the treating physician under the existing care plan.
What the referring physician did vs. what Reserve Meds did
| Referring physician | Reserve Meds |
|---|---|
| Established the diagnosis and second-line indication. | Ran KYC, AML, and OFAC on patient and payer. |
| Wrote the prescription on letterhead. | Sourced the therapy through licensed US wholesale and held DSCSA chain of custody to export. |
| Provided the treatment summary on patient consent. | Issued indicative quote, then firm quote post-document review. |
| Remained the medical decision-maker through dose administration. | Coordinated cold-chain logistics, customs, and Importer-of-Record for the destination country. |
| Held the ongoing clinical relationship with the patient. | Delivered to the treating clinic and closed the file with signed delivery confirmation. |
Outcome
Day 12, ground to arrival.
The patient received the indicated therapy on Day 12. The treating physician retained the clinical relationship and continued the patient's care without interruption.
Cost transparency
An indicative range was disclosed before document review so the family could decide whether to proceed.
A firm quote was issued only after prescription, identity, and shipping documentation were in hand.
No specific figures appear in this case because the framing is the value: range first, firm quote on documents.